Therapeutic strategies that target angiogenesis and vasculogenesis hold great promise in the treatment of cancer (1-7). During the last decade, many new angiogenesis inhibitors have been identified, and several have shown efficacy against tumor growth in vivo (8, 9) . However, results of early clinical trials with these inhibitors have not yet paralleled the success achieved in animal models (10, 11) . Although there are several plausible explanations for this incongruity, a key factor may be the heterogeneous composition of growing tumors, which is directly linked to the plasticity of tumor cells. The heterogeneity of the vascular supply to a growing tumor is also a critical factor for tumor survival (12,13). A recent gene expression profiling study revealed that aggressive melanoma cells express genes whose expression is associated with different cellular phenotypes, including genes that are usually expressed by endothelial, epithelial, hematopoietic, or kidney cells; by pericytes; or by several other cell types (14). These results suggest that aggressive melanoma cells might be capable of reverting to an undifferentiated, plastic phenotype.
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Additional studies have demonstrated that melanoma cells have a vascular phenotype that is characterized by their ability to form tubular networks when grown in three-dimensional (3-D) culture, concomitant with their expression of genes typically expressed by endothelial cells, phenomena referred to as vasculogenic mimicry (15, 16) . These observations have prompted us to investigate the potential relevance of a plastic tumor cell phenotype because they challenge our current thinking about how to identify and target tumor cells that might masquerade as endothelial cells or other cell types. Thus, we examined the effects of specific angiogenesis inhibitors on melanoma cells to see if they inhibit vasculogenic mimicry in a manner similar to the way they inhibit endothelial celldriven angiogenesis.
To test this premise, we treated human endothelial and melanoma cells (seeded at an initial density of 100 000 cells/well on 12-well plates containing 3-D Matrigel or collagen I) with one of three angiogenesis inhibitors of differing specificities-anginex (17) , , or endostatin (19)-or the aqueous-based vehicle only-for various times and examined the effects of the treatments on the ability of the cells to form vascular cords and tubular networks. We used human metastatic melanoma MUM-2B (uveal) and C8161 (cutaneous) cells, which form tubular structures with lumen(s) and networks when cultured on 3-D collagen matrices (15, 16) , and human microvascular endothelial cells (20) ] and human umbilical vein endothelial cells (HUVECs), which form cords and vascular networks when cultured on Matrigel or 3-D collagen matrices (15, 16) . MUM-2B cells were cloned from a heterogeneous MUM-2 uveal melanoma cell line derived from a liver metastasis (21); C8161 cells were isolated from an abdominal wall metastasis (22) . Data were photographically recorded daily; the endothelial cell cultures were morphologically assessed using bright-field microscopy; the melanoma cultures were stained with periodic acid Schiff to visualize tubular networks. Histologic cross-sections of these networks were stained with hematoxylin-eosin to assess luminal integrity. The average total length and mean total number of junctions for treated and control endothelial cords were further analyzed using twosided Mann-Whitney U tests (17, 18) .
As shown in Fig. 1 (panels A, D, G, J, and M), HMEC-1 cells treated with each of the three angiogenesis inhibitors had statistically significantly shorter cords and fewer junctions (a measure of the extent of vascular network formation) (23) than HMEC-1 cells treated with the corresponding vehicle. For example, compared with vehicle control, 25 M anginex and 10 M anginex decreased mean cord length by 71% (95% confidence interval [CI] ϭ 44% to 98% decrease; PϽ.001) and 63% (95% CI ϭ 38% to 88% decrease; P ϭ .001), respectively; 25 M anginex and 10 M anginex decreased the mean number of junctions by 73% (95% CI ϭ 52% to 94% decrease; PϽ.001) and 73% (95% CI ϭ 50% to 93% decrease; PϽ.001), respectively. Compared with vehicle control, 100 ng of TNP-470/mL, 30 ng of TNP-470/mL, and 10 ng of TNP-470/mL decreased the average cord length by 57% (95% CI ϭ 42% to 72% decrease; P ϭ .007), 31% (95% CI ϭ 18% to 45% decrease; P ϭ .008), and 21% (95% CI ϭ 12% to 30% decrease; P ϭ .038), respectively. Compared with vehicle control, 100 ng of TNP-470/mL, 30 ng of TNP-470/mL, and 10 ng of TNP-470/mL decreased the mean number of junctions by 46% (95% CI ϭ 29% to 63% decrease; PϽ.001), 53% (95% CI ϭ 33% to 74% decrease; P ϭ .011), and 33% (95% CI ϭ 22% to 45% decrease; P ϭ .035), respectively. Compared with vehicle control, 10 g of endostatin/mL decreased the average cord length by 94% (95% CI ϭ 86% to 100% decrease; P ϭ .005) and the mean number of junctions by 75% (95% CI ϭ 49% to 100% decrease; PϽ.001). We obtained identical results with HUVECs under similar experimental conditions (data not shown).
By contrast, we observed no statistically significant difference in mean total cord length or in mean total number of junctions in C8161 or MUM-2B melanoma cells treated with these drugs at any concentration and the corresponding cells treated with the vehicle (data not shown). Both anginex and TNP-470 have been described as being cytotoxic for activated endothelial cells in previous studies (17, 18) ; endostatin has been shown to be an inhibitor of endothelial cell migration (19) . By comparison, none of the angiogenesis inhibitors, at any concentration, had a statistically significant effect on melanoma cell vasculogenic mimicry, specifically on the ability of melanoma cells to form extracellular matrix-rich vasculogenic-like networks in 3-D matrices, compared with vehicle-treated control cells (Fig. 1 , B, C, E, F, H, I, K, and L). Analysis of histologic cross-sections of the networks formed by MUM-2B cells treated with the angiogenesis inhibitors revealed that the morphologic integrity of the tubular structures that contained lumens remained undisrupted compared with that of vehicle-treated control MUM-2B cells (insets of Fig. 1, C, F, I , and L). Thus, these comparative analyses revealed that these angiogenesis inhibitors All experiments were performed in triplicate (n ϭ 3 to 8 parameters/test) and analyzed using the two-sided Mann-Whitney U test. Left panel: *, statistically significant differences in the mean total cord length between control and 25 M anginex (PϽ.001); 10 M anginex (P ϭ .001); 100 ng/mL TNP-470 (P ϭ .007); 30 ng/mL TNP-470 (P ϭ .008); 10 ng/mL TNP-470 (P ϭ .038); and 10 g/mL endostatin (P ϭ .005). Right panel: *, statistically significant differences in the mean total number of junctions between control and 25 M anginex (PϽ.001); 10 M anginex (PϽ.001); 100 ng/mL TNP-470 (PϽ.001); 30 ng/mL TNP-470 (P ϭ .011); 10 ng/mL TNP-470 (P ϭ .035): and 10 g/mL endostatin (PϽ.001). Error bars correspond to 95% confidence intervals.
were effective against endothelial cells but not against aggressive melanoma tumor cells. Similar results have been reported by Rybak et al. (23) in the B16F10 murine melanoma model with TNP470, one of the antiangiogenic drugs used in our study.
The process of angiogenesis requires cell growth and migration as well as tube assembly. Therefore, we examined the effect of the three angiogenesis inhibitors on endothelial and melanoma cell growth over the course of 6 days, starting with 5000 cells seeded per well. As shown in Fig. 2 , A, anginex and TNP-470 resulted in statistically significant inhibition of endothelial cell proliferation (25 M anginex versus control: 83% decrease in proliferation [95% CI ϭ 76% to 89%; P ϭ .002]; 100 ng of TNP-470/mL versus control: 80% decrease in proliferation [95% CI ϭ 72% to 89%; P ϭ .003]); by contrast, endostatin had no statistically significant effect on the proliferation of endothelial cells or melanoma cells. However, 25 M anginex statistically significantly inhibited the proliferation of C8161 cells compared with control (64% decrease, 95% CI ϭ 52% to 77% decrease; P ϭ .045), and 100 ng of TNP-470/mL statistically significantly inhibited the proliferation of MUM-2B cells compared with control (60% decrease compared with control, 95% CI ϭ 47% to 73% decrease; P ϭ .047). The observation that TNP-470 increased the proliferation of C8161 cells (166% increase compared to control, 95% CI ϭ 156% to 176% increase; P ϭ .016) is contrary to what occurred with endothelial cells in this study and merits further examination.
To examine one possible basis for the effects of the angiogenesis inhibitors on cell proliferation, we used flow cytometry to measure the extent of apoptosis among cells treated with the various angiogenesis inhibitors and found that HUVECs were more sensitive to each of the three inhibitors (i.e., they had higher levels of apoptotic cells) than either of the melanoma cell lines and that 25 M anginex induced the highest levels of apoptosis (1036% increase compared with control, 95% CI ϭ 857% to 1217% increase; P ϭ .023), followed by endostatin (271% increase compared with control, 95% CI ϭ 137% to 405% in- 3 H]thymidine incorporation, as previously described (17) , and analyzed using two-sided Mann-Whitney U tests. *, statistically significant differences in proliferation between control-treated and anginex-treated HUVEC (P ϭ .002) and C8161 cells (P ϭ .045), and between control-treated and TNP-470 -treated HUVEC (P ϭ .003), MUM-2B cells (P ϭ .047), and C8161 cells (P ϭ .016). B) Percentage of apoptotic C8161, MUM-2B, and HUVEC cells in response to anginex, TNP-470, and endostatin compared with vehicle-treated control cells, measured as a subdiploid peak using flow cytometry, was analyzed using the two-sided Mann-Whitney U test. *, statistically significant differences compared with control (anginex: P ϭ .023; endostatin: P ϭ .047). (Error bars correspond to 95% confidence intervals.) C) Semiquantitative reverse transcription-polymerase chain reaction (PCR) demonstrating the relative expression levels of integrin ␣ 5 -subunit and HSPG2 in untreated HUVEC, C8161, and MUM-2B cells. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used as controls for PCR amplification, and relative expression levels were quantified using ScionImage Beta 4.0.2 software (Scion Corp., Frederick, MD) normalized against GAPDH expression. Numbers represent relative areas of intensity versus control. D, E) Western blot analysis of ␣ 5 -integrin subunit (D) and HSPG2 (E) levels in whole-cell lysates of untreated C8161, MUM-2B, HUVEC, and HMEC-1 cells using primary antibodies (Chemicon AB1928 and US Biological H1890 -93, respectively) according to the manufacturers' suggested antibody dilutions, followed by an appropriate horseradish peroxidase-conjugated secondary antibody (Amersham Biosciences, Piscataway, NJ), and enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate; Pierce, Rockford, IL). A ␤-actin antibody (MAB1501; Chemicon) was used as a control for equal loading, and relative amounts of protein were determined from digital images obtained using ScionImage normalized against the ␤-actin controls. Numbers represent relative areas of intensity versus control. F) Mean fluorescence (determined by fluorescence-activated cell sorter analysis of 10 4 events) of HSPG2 (detected by using antibody CBL 497F; Chemicon) in untreated C8161, MUM-2B, HUVEC, and HMEC-1 cells. All experiments (C-F) were performed in duplicate.
crease; P ϭ .047) (Fig. 2, B) . Identical results were obtained with HMEC-1 cells (data not shown). By contrast, neither melanoma cell line showed statistically significant changes in their respective apoptotic indices when treated with any of the three inhibitors compared with vehicle-treated control cells. These data demonstrate that endothelial cells and melanoma cells respond dramatically differently to angiogenesis inhibitors with respect to the induction of apoptosis. Interestingly, previous findings have shown that co-cultures of aggressive vasculogenic melanoma MUM-2B cells and endothelial HUVEC or HMEC-1 cells result in cell lysis of endothelia within 48 hours (24) , suggesting a complex interaction between these two cell populations. The differential response of endothelial cells and melanoma cells to angiogenesis inhibitors that we report here may provide additional insight into the mechanistic interactions between endothelia and proliferating tumors (and demonstrate dual targets for antivascular drug therapy).
Finally, to address a possible mechanistic basis for the different effects of the inhibitors on endothelial and melanoma cells, we used semiquantitative reverse transcription-polymerase chain reaction, Western blot, and fluorescence-activated cell sorter analyses to examine whether endothelial cells and melanoma cells expressed different levels of the recently reported receptors for endostatin, ␣ 5 ␤ 1 integrin (25) and heparin sulfate proteoglycan 2 (HSPG2; also known as perlecan, 26, 27) . We found that endothelial HUVEC cells displayed robust expression of HSPG2 and the integrin ␣ 5 -subunit at the mRNA and protein levels (Fig. 2, C-F) . By contrast, the melanoma cells expressed only modest levels of integrin ␣ 5 -subunit mRNA and protein and barely detectable levels of HSPG2 mRNA and protein.
Thus, these data reveal that the receptors for one of the angiogenesis inhibitors tested, endostatin, are differentially expressed in the endothelial and melanoma cells. This observation of vastly different levels of the integrin ␣ 5 -subunit and HSPG2 may provide important clues as to the disparate responses of these cell types to antivascular therapy. HSPG2 is considered an excellent target for antiangiogenic therapy because it has been shown to play a key role in mediating basic fibroblast growth factor stimulation of endothelial cell-driven angiogenesis (28) . The ␣ 5 integrin is critical for endothelial blood vessel formation, and thus, agents targeting this integrin are likely to be effective against angiogenesis (29). Our data reveal biologically significant differences in the response of endothelial cells and aggressive melanoma cells that are engaged in vasculogenic mimicry to select angiogenesis inhibitors. Because vasculogenic mimicry has been reported in several other tumor models, including breast, prostatic, ovarian, and lung carcinoma [reviewed in Hendrix et al. (30) ], these findings may offer new insights for designing rational antivascular therapeutic approaches in a broader context.
